Multiple predicted AD-related targets

Multiple predicted AD-related targets is a non-specific descriptor used to categorize a group of biological entities, typically proteins or genes, that have been computationally linked to the pathogenesis of Alzheimer's Disease (AD). This term does not identify a single, actionable therapeutic target such as a specific receptor or enzyme, but instead refers to a collection of candidates derived from large-scale genomic, proteomic, or transcriptomic studies, such as those conducted by the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) (NIH, 2023). Such lists are often produced to prioritize novel areas for drug discovery by integrating multi-omics data to identify gene networks associated with AD progression (Logsdon et al., 2019). Because the term encompasses a diverse array of molecules with varying biological roles, it lacks a singular molecular classification, biological function, or mechanism of action. From a drug development perspective, this entry is considered incorrect or insufficient as it provides a heterogeneous set of information without a specific molecular identity. Individual targets within such a group must be isolated and validated independently to assess their potential for therapeutic intervention and safety (Hodes & Buckholtz, 2016). Consequently, there are no specific interacting drugs or established biomarkers associated with this collective heading. The designation serves as a placeholder in bioinformatics datasets rather than a defined pharmacological target.

Not applicable